vs
Side-by-side financial comparison of Bloomin' Brands, Inc. (BLMN) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Bloomin' Brands, Inc. is the larger business by last-quarter revenue ($1.1B vs $708.5M, roughly 1.5× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 5.4%, a 13.7% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 1.0%). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 3.0%).
Bloomin' Brands, Inc. is a restaurant holding company that owns several American casual dining restaurant chains. The company was established in 1988 in Tampa, Florida, where it is headquartered.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
BLMN vs MEDP — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $708.5M |
| Net Profit | $57.2M | $135.1M |
| Gross Margin | — | — |
| Operating Margin | 5.6% | 21.6% |
| Net Margin | 5.4% | 19.1% |
| Revenue YoY | 1.0% | 32.0% |
| Net Profit YoY | — | 15.5% |
| EPS (diluted) | $0.64 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $975.2M | $708.5M | ||
| Q3 25 | $928.8M | $659.9M | ||
| Q2 25 | $1.0B | $603.3M | ||
| Q1 25 | $1.0B | $558.6M | ||
| Q4 24 | $972.0M | $536.6M | ||
| Q3 24 | $910.0M | $533.3M | ||
| Q2 24 | $999.4M | $528.1M |
| Q1 26 | $57.2M | — | ||
| Q4 25 | $-13.5M | $135.1M | ||
| Q3 25 | $-45.9M | $111.1M | ||
| Q2 25 | $25.4M | $90.3M | ||
| Q1 25 | $42.2M | $114.6M | ||
| Q4 24 | $-79.5M | $117.0M | ||
| Q3 24 | $6.9M | $96.4M | ||
| Q2 24 | $28.4M | $88.4M |
| Q1 26 | — | — | ||
| Q4 25 | 70.2% | — | ||
| Q3 25 | 70.4% | — | ||
| Q2 25 | 70.2% | — | ||
| Q1 25 | 70.1% | — | ||
| Q4 24 | 71.6% | — | ||
| Q3 24 | 71.3% | — | ||
| Q2 24 | 70.5% | — |
| Q1 26 | 5.6% | — | ||
| Q4 25 | -1.4% | 21.6% | ||
| Q3 25 | -3.9% | 21.5% | ||
| Q2 25 | 3.0% | 20.9% | ||
| Q1 25 | 5.5% | 20.3% | ||
| Q4 24 | 1.7% | 23.4% | ||
| Q3 24 | 0.9% | 21.1% | ||
| Q2 24 | 4.4% | 19.9% |
| Q1 26 | 5.4% | — | ||
| Q4 25 | -1.4% | 19.1% | ||
| Q3 25 | -4.9% | 16.8% | ||
| Q2 25 | 2.5% | 15.0% | ||
| Q1 25 | 4.0% | 20.5% | ||
| Q4 24 | -8.2% | 21.8% | ||
| Q3 24 | 0.8% | 18.1% | ||
| Q2 24 | 2.8% | 16.7% |
| Q1 26 | $0.64 | — | ||
| Q4 25 | $-0.16 | $4.65 | ||
| Q3 25 | $-0.54 | $3.86 | ||
| Q2 25 | $0.30 | $3.10 | ||
| Q1 25 | $0.50 | $3.67 | ||
| Q4 24 | $-0.93 | $3.67 | ||
| Q3 24 | $0.08 | $3.01 | ||
| Q2 24 | $0.32 | $2.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $71.3M | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $398.8M | $459.1M |
| Total Assets | $3.1B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $71.3M | — | ||
| Q4 25 | $59.5M | $497.0M | ||
| Q3 25 | $66.5M | $285.4M | ||
| Q2 25 | $50.3M | $46.3M | ||
| Q1 25 | $57.7M | $441.4M | ||
| Q4 24 | $70.1M | $669.4M | ||
| Q3 24 | $83.6M | $656.9M | ||
| Q2 24 | $117.9M | $510.9M |
| Q1 26 | — | — | ||
| Q4 25 | $787.4M | — | ||
| Q3 25 | $962.2M | — | ||
| Q2 25 | $917.1M | — | ||
| Q1 25 | $917.6M | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.0B | — |
| Q1 26 | $398.8M | — | ||
| Q4 25 | $333.6M | $459.1M | ||
| Q3 25 | $344.1M | $293.6M | ||
| Q2 25 | $397.2M | $172.4M | ||
| Q1 25 | $380.6M | $593.6M | ||
| Q4 24 | $135.5M | $825.5M | ||
| Q3 24 | $242.1M | $881.4M | ||
| Q2 24 | $286.8M | $763.6M |
| Q1 26 | $3.1B | — | ||
| Q4 25 | $3.2B | $2.0B | ||
| Q3 25 | $3.3B | $1.8B | ||
| Q2 25 | $3.3B | $1.6B | ||
| Q1 25 | $3.3B | $1.9B | ||
| Q4 24 | $3.4B | $2.1B | ||
| Q3 24 | $3.4B | $2.1B | ||
| Q2 24 | $3.4B | $1.9B |
| Q1 26 | — | — | ||
| Q4 25 | 2.36× | — | ||
| Q3 25 | 2.80× | — | ||
| Q2 25 | 2.31× | — | ||
| Q1 25 | 2.41× | — | ||
| Q4 24 | 7.58× | — | ||
| Q3 24 | 4.51× | — | ||
| Q2 24 | 3.49× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $192.7M |
| Free Cash FlowOCF − Capex | — | $188.1M |
| FCF MarginFCF / Revenue | — | 26.6% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | — | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $119.1M | $192.7M | ||
| Q3 25 | $34.4M | $246.2M | ||
| Q2 25 | $49.7M | $148.5M | ||
| Q1 25 | $73.5M | $125.8M | ||
| Q4 24 | $119.8M | $190.7M | ||
| Q3 24 | $-7.8M | $149.1M | ||
| Q2 24 | $42.4M | $116.4M |
| Q1 26 | — | — | ||
| Q4 25 | $63.7M | $188.1M | ||
| Q3 25 | $-5.7M | $235.5M | ||
| Q2 25 | $11.1M | $142.4M | ||
| Q1 25 | $27.7M | $115.8M | ||
| Q4 24 | $66.7M | $183.0M | ||
| Q3 24 | $-67.3M | $138.5M | ||
| Q2 24 | $-12.1M | $103.5M |
| Q1 26 | — | — | ||
| Q4 25 | 6.5% | 26.6% | ||
| Q3 25 | -0.6% | 35.7% | ||
| Q2 25 | 1.1% | 23.6% | ||
| Q1 25 | 2.6% | 20.7% | ||
| Q4 24 | 6.9% | 34.1% | ||
| Q3 24 | -7.4% | 26.0% | ||
| Q2 24 | -1.2% | 19.6% |
| Q1 26 | — | — | ||
| Q4 25 | 5.7% | 0.6% | ||
| Q3 25 | 4.3% | 1.6% | ||
| Q2 25 | 3.8% | 1.0% | ||
| Q1 25 | 4.4% | 1.8% | ||
| Q4 24 | 5.5% | 1.4% | ||
| Q3 24 | 6.5% | 2.0% | ||
| Q2 24 | 5.5% | 2.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 2.22× | ||
| Q2 25 | 1.95× | 1.65× | ||
| Q1 25 | 1.74× | 1.10× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | -1.13× | 1.55× | ||
| Q2 24 | 1.49× | 1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLMN
| Restaurant sales | $1.0B | 97% |
| Franchise and other revenues | $10.3M | 1% |
| Franchise revenues (1) | $7.6M | 1% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
